In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Caleb Alexander about the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.
Click here to read the transcript.
G. Caleb Alexander, MD, MS is professor of epidemiology and medicine at Johns Hopkins Bloomberg School of Public Health.
Recorded on June 22, 2021
Conflict of Interest Disclosure
Dr Alexander is past chair and current member of FDA's Peripheral and Central Nervous System Drugs Advisory Committee. He is a co-founding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. He was also a member of OptumRx's National Pharmacy and Therapeutics Committee.
Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.